1. Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control.
- Author
-
Vollmuth Y, Alelq NA, Sattler F, Schmidt S, and Hauck F
- Subjects
- Humans, Infant, Male, Treatment Outcome, Skin pathology, Female, Netherton Syndrome diagnosis, Netherton Syndrome drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects
- Abstract
Purpose: Netherton syndrome (NS) is a rare inborn error of immunity (IEI) with an incidence of approximately 1:200,000 and the phenotypic triad of trichorrhexis invaginate (bamboo hair), congenital ichthyosiform erythroderma, and multiple atopic manifestations. Treatment options especially in infants are scarce and generally not licensed., Methods: Case report of a 9-week-old infant with NS treated with dupilumab off-label., Results: We report rapid and sustained resolution of allergic inflammation, deep symptom control including normalization of the skin microbiome, and catch-up somatic and psychomotor development without adverse drug reactions., Conclusion: Due to the high complication rate of NS, especially in the first years of life, we recommend treatment with dupilumab off-label immediately after the diagnosis has been established., Competing Interests: Declarations Competing Interests The authors have no conflicts of interest to disclose., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF